Abstract Details

Title Elevated Plasma Ptau Is Associated with Congestive Heart Failure

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P7 - Poster Session 7 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-008

Objective To determine whether plasma p-tau181 is associated with prevalent and incident cardiovascular disease (CVD).

Background Plasma p-tau181 is a promising AD biomarker for clinical use that has been demonstrated to accurately identify clinical Alzheimer’s disease(AD), align with AD pathology on autopsy, and predict future cognitive decline in research cohorts. However, recent studies in clinical cohorts have raised concerns regarding the effect of medical comorbidities, such as cardiovascular and renal disease, on plasma p-tau181 specificity. These influences must be better understood to enable appropriate clinical use of p-tau181. We sought to evaluate the association between p-tau181 and CVD outcomes in the Framingham Heart Study(FHS).

Design/Methods The FHS is a community-based longitudinal cohort study with deep-phenotyping of CVD. P-tau181 levels were measured from stored samples of 2543 participants from 2011-2014 (Offspring and Omni Cohorts, age 71±8, 55% female, 22% APOE4+) using Quanterix Simoa. CVD outcomes (binary:yes/no) included coronary heart disease, congestive heart failure(CHF), stroke/TIA, and peripheral arterial disease. Multivariate logistic regressions were performed to assess the association between p-tau181 and each prevalent CVD outcome adjusting for age, sex, cohort, eGFR, and BMI. Cox regression models were performed to assess the association between p-tau181 and incident CVD outcomes adjusting for similar covariates after a median follow-up of 7.0 years [5.8-7.6]).

Results At baseline, elevated p-tau181 was associated with prevalent CHF(OR 1.73; 95%CI[1.01-2.97]). Longitudinally, elevated p-tau181 was associated with greater future risk of CHF (HR 1.54[1.02-2.32]). There was no association between p-tau181 levels and other CVD outcomes in cross-sectional or longitudinal analyses.

Conclusions Plasma p-tau181 levels are associated with prevalent and incident CHF in a community-based population. This suggests p-tau181 levels should be interpreted with caution in patients with CHF until the link between p-tau181 and CHF can be further evaluated. Studies to understand medical comorbidities that influence plasma AD biomarkers are necessary prior to widespread clinical use.

Authors/Disclosures
Jeremy Tanner, MD (UTHSA - Neurology) PRESENTER	An immediate family member of Dr. Tanner has received personal compensation for serving as an employee of Channeling Hope Foundation. The institution of Dr. Tanner has received research support from NIA, NINDS. Dr. Tanner has a non-compensated relationship as a Chief Scientific Officer with Channeling Hope Foundation that is relevant to AAN interests or activities.
Crystal Wiedner (UT Health San Antonio)	No disclosure on file
Dibya Himali	No disclosure on file
Jaime Ramos-Cejudo (NYU Grossman School of Medicine)	Jaime Ramos-Cejudo has nothing to disclose.
Alexa Beiser	Alexa Beiser has nothing to disclose.
Sudha Seshadri, MD, FAAN (Glenn Biggs Institute for Alzheimer'S and Neurodegenerative Diseases)	Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Seshadri has received research support from NIH. The institution of Dr. Seshadri has received research support from Alzheimer Association.
Hugo Javier Aparicio, MD, MPH (Boston University)	Dr. Aparicio has received research support from ��ɫ��. Dr. Aparicio has received research support from Alzheimer's Association. Dr. Aparicio has received research support from National Institutes of Health. Dr. Aparicio has received personal compensation in the range of $10,000-$49,999 for serving as a expert panelist for the Memory & Healthy Aging Program with Cedars-Sinai.
Jayandra Himali	Jayandra Himali has nothing to disclose.

��ɫ����

��ɫ����

��ɫ��

��ɫ��